Related Experiment Video
Updated: Nov 16, 2025

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
Published on: March 23, 2022
Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population
Enrique Rodríguez-Rubio1, Helena Gil-Peña2, Sara Chocron3
1Pediatric Research, Medicine Department, University of Oviedo, Oviedo, Spain. erodrr00@gmail.com.
Insights
X-linked hypophosphatemia (XLH) in Spanish children often presents with rickets and growth issues. Conventional treatment with phosphate and vitamin D failed to improve growth or correct low phosphate levels, posing risks of hyperparathyroidism and nephrocalcinosis.
Area of Science:
- Pediatric Endocrinology
- Rare Genetic Diseases
- Skeletal Dysplasias
Background:
- X-linked hypophosphatemia (XLH) is a rare genetic disorder caused by PHEX gene mutations.
- It leads to hypophosphatemia and renal phosphate wasting, manifesting as rickets and growth retardation in children.
- Phenotypic variability exists, necessitating further studies on clinical spectrum and outcomes.
Purpose of the Study:
- To analyze the clinical spectrum, genotype-phenotype correlations, and long-term outcomes of XLH in Spanish pediatric patients.
- To evaluate the efficacy and safety of conventional treatment for XLH.
- To provide data for the development of new therapeutic strategies.
Main Methods:
- Retrospective analysis of 48 Spanish pediatric patients with genetically confirmed XLH from the RenalTube database.
- Data collection included clinical manifestations, biochemical parameters, genetic analysis, and treatment outcomes.
- Median follow-up duration was 7.42 years for treatment efficacy assessment.
Main Results:
- Rickets and growth retardation were the most common findings at diagnosis in XLH patients.
- Mean height was -1.89 SDS, with 55% of patients below -2 SDS.
- Conventional treatment with phosphate and vitamin D did not improve height or normalize serum phosphate levels.
- No genotype-phenotype correlation was observed.
- Eleven patients developed mild hyperparathyroidism, and 8 developed nephrocalcinosis.
Conclusions:
- Growth retardation and rickets are highly prevalent in pediatric XLH.
- Conventional treatment is ineffective for improving height and correcting hypophosphatemia in XLH.
- Conventional treatment carries risks of hyperparathyroidism and nephrocalcinosis.
- XLH severity is similar in both genders.
Background:
X-linked hypophosphatemia (XLH) is a hereditary rare disease caused by loss-of-function mutations in PHEX gene leading tohypophosphatemia and high renal loss of phosphate. Rickets and growth retardation are the major manifestations of XLH in children, but there is a broad phenotypic variability. Few publications have reported large series of patients. Current data on the clinical spectrum of the disease, the correlation with the underlying gene mutations, and the long-term outcome of patients on conventional treatment are needed, particularly because of the recent availability of new specific medications to treat XLH.
Results:
The RenalTube database was used to retrospectively analyze 48 Spanish patients (15 men) from 39 different families, ranging from 3 months to 8 years and 2 months of age at the time of diagnosis (median age of 2.0 years), and with XLH confirmed by genetic analysis. Bone deformities, radiological signs of active rickets and growth retardation were the most common findings at diagnosis. Mean (± SEM) height was - 1.89 ± 0.19 SDS and 55% (22/40) of patients had height SDS below-2. All cases had hypophosphatemia, serum phosphate being - 2.81 ± 0.11 SDS. Clinical manifestations and severity of the disease were similar in both genders. No genotype-phenotype correlation was found. Conventional treatment did not attenuate growth retardation after a median follow up of 7.42 years (IQR = 11.26; n = 26 patients) and failed to normalize serum concentrations of phosphate. Eleven patients had mild hyperparathyroidism and 8 patients nephrocalcinosis.
Conclusions:
This study shows that growth retardation and rickets were the most prevalent clinical manifestations at diagnosis in a large series of Spanish pediatric patients with XLH confirmed by mutations in the PHEX gene. Traditional treatment with phosphate and vitamin D supplements did not improve height or corrected hypophosphatemia and was associated with a risk of hyperparathyroidism and nephrocalcinosis. The severity of the disease was similar in males and females.
Related Concept Videos
Sex-linked Disorders
Pedigree Analysis
Inborn Errors of Metabolism
Pharmacokinetics in Pediatric Patients: Drug Metabolism
X-linked Traits
Lethal Alleles
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...

